Waters to buy Becton Dickinson unit in a $17.5 billion deal amid tariff pressures

Waters Corp will acquire a bioscience and diagnostics unit from Becton Dickinson for $17.5 billion in a stock-and-cash transaction, enabling BD to divest an underperforming, tariff-sensitive segment and focus on core medtech, while Waters doubles its total addressable market to $40 billion with a projected 5-7% annual growth. Despite the tax-efficient Reverse Morris Trust structure and Waters CEO's integration experience, investor reaction was cautious, with Waters shares down 11.5% and BD shares down 0.7%, reflecting concerns from analysts regarding the deal's complexity and execution risks.

Analysis

Waters Corp is executing a transformative acquisition of Becton Dickinson's bioscience and diagnostics unit for $17.5 billion in a stock-and-cash deal structured as a tax-efficient Reverse Morris Trust. This strategic move is poised to double Waters' total addressable market to approximately $40 billion, with a projected 5% to 7% annual growth rate. For Becton Dickinson, the transaction represents a strategic divestiture of an underperforming, tariff-sensitive business, enabling a sharpened focus on its core medical technology operations. Despite the strategic merits, the market has responded with significant caution, reflected by an 11.5% drop in Waters' shares, while Becton Dickinson's stock fell a marginal 0.7%. This reaction aligns with analyst commentary from JP Morgan and Jefferies, which highlights considerable execution risk and added complexity to Waters' growth narrative. The deal's success is heavily dependent on the integration led by Waters CEO Udit Batra, whose prior experience with the $17 billion Merck KGaA acquisition of Sigma-Aldrich is cited as a key factor that could mitigate these integration challenges. Waters will assume an additional $4 billion in debt as part of the transaction, a key financial consideration for investors.

Key Decisions for Investors

• Investors in Waters Corp should weigh the substantial execution risk, priced in by the 11.5% share decline, against the long-term potential of a doubled addressable market and the CEO's strong M&A integration track record.
• For Becton Dickinson shareholders, this divestiture can be viewed as a positive de-risking event that enables a more focused strategy on its core, higher-margin medtech business.
• Given the deal's complexity and the new debt on Waters' balance sheet, it is prudent to monitor the combined entity's initial quarterly reports for tangible evidence of synergy realization and margin performance before increasing exposure.